#### SIMULTANEOUS QUANTITATIVE DETERMINATION OF TINIDAZOLE DILOXANIDE FUROATE AND IN TABLET PREPARATIONS BY DIFFERENCE SPECTROSCOPY

P.Parimoo and P.Umapathi

Department of Pharmacy Birla Institute of Technology and Science Pilani Rajasthan India-333 031

### **ABSTRACT**

A difference spectrophotometric procedure has been developed for the simultaneous determination (TD) and Diloxanide furoate (DF) in tablet preparations. The method comprised the measurement of a solution of the tablet extract absorbance in 2.0 buffer solution relative to that of an solution in pH 13.0 buffer at the wavelengths of and 240nm. The presence of identical isosbestic points drug samples and tablet extract solutions for pure the non-interference of excipients absorption at these wavelengths. The compliance Beer's Law was obtained in the concentration range o f 20-40μg/ml for TD and DF at these wavelengths.



# INTRODUCTION

Difference spectrophotometry is the technique involves the reproducible alteration of which spectral properties of the analyte in equimolar solutions and the measurement of the absorbance difference(8A) between two solutions. Its advantages selective analysis of drugs without specific interferences have been described by some workers. combination of TD and DF is widely used for acute 3 chronic intestinal amoebiasis and hepatic amoebiasis. methods have been reported for the individual 6,7,8. of TD and DF but there are no assay about their simultaneous determination in the presence of each other. The later is being discussed in the present research work.

# EXPERIMENTAL

#### Standard and Sample Solutions

Appropriate aliquots of stock solutions of pure TD (1mg/ml) and DF(1mg/ml) in methanol were used prepare two series of equimolar solutions of each drug in pH 2.0 and 13.0 buffers containing 20-40µg/ml of TD (series I) and 20-40μg/ml of DF (series II). Similarly, more series of equimolar solutions of mixtures






FIGURE 1.

Tinidazole Difference Absorption Spectra рH 2.0 13.0 solutions versus рĦ )  $20\mu g/ml$ (x-x-x-x)  $30\mu g/ml$ (-○-○-○- ) 40µg/ml




FIGURE 2.

Difference Absorption Spectra o f Diloxanide pH 2.0 versus pH 13.0 Buffer Solutions in (x-x-x-x) 30µg/ml (-○-○-) 40µg/ml



TABLE 1 Assay Results of Tinidazole and Diloxanide furoate in Commercial Formulations by Difference Spectroscopy.

Sample		TD		DF
	mg/tab	‱v/w stated*	mg/tab	‱v/w stated*
Brand A	298.5	99.50 ± 0.4621	498.8	99.76 ± 0.5156
Brand B	297.3	99.10 ± 0.2302	498.0	96.60 ± 0.2701
Brand C	299.4	99.80 ± 0.3391	247.5	99.00 ± 0.3898

<sup>\*</sup> Five replicate measurements

TD and DF. the first containing a constant concentration of 30μg/ml of DF and a varving concentration of 20-40µg/ml of TD (series III) second containing a constant concentration of 30µg/ml TD and a varying concentration of 20-40µg/ml of (series IV) were prepared with the buffers.

Twenty tablets were accurately weighed, powdered a weight of the powder equivalent to 50mg of TD (and 83mg or 41mg of DF) was dissolved in methanol, filtered, and appropriate volumes of the aliquots were diluted with the buffers to obtain equimolar solutions containing approximately 25µg/ml of TD and 40µg/ml of DF respectively .



The absorbance difference of the acidic and equimolar drug solutions were measured from 230-350nm with Jasco 7800 uv-visible double spectrophotometer. The results are given in Table 2.

### RESULTS AND DISCUSSION

The δA values of standard solutions of TD  $(25\mu g/ml)$ and  $DF(40\mu g/ml)$  relative to  $\delta A$ οf tablet sample solution was used for the determination DF in the tablet preparation. The concentration TD and DF in the tablet contents of average weight as a percentage of stated quantity of drug were calculated using well established procedure. The results are given in Table 1.

wavelengths of \$A value maxima, minima isosbestic points (a wavelength of zero &A due to equal absorptivities of the two species) of TD and spectra are shown in Fig 1 and 2 respectively. wavelengths of 282nm and 240nm were chosen estimation of TD and DF since the &A values of their spectra were more optimal for accurate difference absorption measurement than the value at the other isosbestic points for the concentrations of TD and in commercial formulations as well as to provide minimum relative error in absorption measurement. The regression equations of the solutions of



TABLE 2 Method Selectivity for the Determination of Tinidazole and Diloxanide furoate bу Difference Spectroscopy

Composit lixture TD		Mean*	(åA)	95% Confidence Limit**
20	20	0.325 ±	0.0022	± 0.0012
30	20	0.484 ±	0.0022	± 0.0021
40	20	0.653 ±	0.0028	± 0.0014
20	20	0.664 ±	0.0037	± 0.0018
20	30	0.992 ±	0.0032	± 0.0015
20	40	1.322 ±	0.0038	± 0.0021

<sup>\*</sup> Ten replicate measurements

I, II, III and IV (mentioned under Standard Solutions) were y = 0.162x + 0.0010 (RE I), y = 0.032x + 0.0025(RE II), y = 0.162x + 0.0025 (RE III) and y = 0.032x - 0.00250.0017 (RE IV) with corresponding correlation coof 0.9984, 0.9998, 0.9986 and 0.9998 efficients respectively. The similarity of RE I to RE III and II to RE IV suggest the non-interference of the absorptivity of the drugs with each other as well as excipients at the isosbestic points.



<sup>\*\*</sup> Based on student's t distribution

### CONCLUSION

Difference spectroscopy may be used analysis of such two component formulations in which isosbestic point of one component lies at or maximum of the difference spectrum of the the The proposed method meets component. requirements. The non-interference of the excipients in is evidenced by the identical determination the isosbestic points in the standard and sample solutions. The similarity of the regression equations indicate the rectilinearity of &A values at the isosbestic points The negligible specificity of the method. and similar correlation co-efficients intercepts confirm the precision and reproducibility of method. Hence the proposed method is found suitable for the simultaneous determination of TD and DF in tablet formulations.

## **ACKNOULEDGEMENT**

The authors are thankful to Messrs.Kopran Ltd. and Wockhardt (India) Ltd. for their gift of pure Tinidazole and Diloxanide furoate.

#### REFERENCES

1. Doyle, T.D. and Fezzari, F.R., J. Pharm. Sci., 63, 1921-1926 (1974).



- Davidson, A.J., J. Pharm. Pharmacol., 28,795-800 (1976) 2.
- Martindale, The Extra Pharmacopoeia, 29th edn., The 3. Pharmaceutical Press, London, 1989, p.663.
- Bhathar R.G. and Vagvankar, C.V., Eastern Pharmacist, 4. 25, 117 (1982)
- Slamik Manjan , J. Pharm. Sci., 65, 736 (1976). 5.
- Shah, P.P. and Mehta, P.C., Ind. J. Pharm. Sci., 43, 6. 147-149 (1981)
- Sanghan, N.M. and Kulkarni, S.P., Ind. J. Pharm. Sci., 7. 40(3), 101 (1978)
- The Pharmacopoeia of India ,3rd edn., Vol I, 8. Ministry of Health and Family Welfare, New Delhi, 1985, p.174.
- Beckett, A.H. and Stenlake, J.B. in Practical 9. Pharmaceutical Chemistry, 3rd edn., Part II, CBS Publishers, New Delhi, 1986, pp.247,274.

